

# Antipsychotics – Virginia Prior Authorization Request Form

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.  
**This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.**  
**Allow at least 24 hours for review.**

Member Information			Prescriber Information		
Member Name:			Provider Name:		
Member ID:			NPI #:		Specialty:
Date Of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	ZIP Code:	Office Street Address:		
Phone:		Allergies:	City:	State:	ZIP Code:
<b>Is the requested medication:</b> <input type="checkbox"/> New or <input type="checkbox"/> Continuation of Therapy? If continuation, list start date: _____ <b>Is this patient currently hospitalized?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No If recently discharged, list discharge date: _____ <b>Is this member pregnant?</b> <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____					
Medication Information					
Medication:				Strength:	
Directions for use:				Quantity:	
Medication Administered: <input type="checkbox"/> Self-Administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Other: _____					
Clinical Information					
What is the patient's diagnosis for the medication being requested? _____					
ICD-10 Code(s): _____					
Are there any supporting laboratory or test results related to the patient's diagnosis? <i>(Please specify or provide documentation)</i>					
Previous Medication Trials / Contraindications					
<b>Please refer to the patient's PDL at <a href="http://www.uhcprovider.com">www.uhcprovider.com</a> for a list of preferred alternatives</b>					
What medication(s) does the patient have a history of <b>failure</b> to? <i>(Please specify ALL medication(s)/strengths tried, directions, length of trial, and reason for discontinuation of each medication)</i>					
What medication(s) does the patient have a <b>contraindication or intolerance</b> to? <i>(Please specify ALL medication(s) with the associated contraindication to or specific issues resulting in intolerance to each medication)</i>					
Additional information that may be important for this review					

Patient First name:	Patient Last name:	Patient DOB:
<b>Clinical and Drug Specific Information</b>		
<b>ALL REQUESTS</b>		
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Does the patient have any of the following diagnoses? (check which applies)</b> <input type="checkbox"/> Autism <input type="checkbox"/> Schizophrenia or schizoaffective disorder <input type="checkbox"/> Bipolar disorder <input type="checkbox"/> Tourette's <input type="checkbox"/> Major depressive disorder	
<b>CHILDREN LESS THAN 18 YEARS OF AGE</b>		
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Is the prescriber a psychiatrist, neurologist, or developmental/behavioral pediatrician?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>If no to the above question, has the provider consulted a psychiatrist, neurologist, or developmental/behavioral pediatrician before prescribing the requested medication?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Has the patient received a developmentally-appropriate, comprehensive psychiatric assessment with diagnoses, impairments, treatment target, and treatment plans clearly identified and documented?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>If no to the above question, is a psychiatric assessment scheduled, or are services not available in the area? (check which applies)</b> <input type="checkbox"/> Psychiatric assessment is scheduled – start date: _____ <input type="checkbox"/> Services are not available in the area <input type="checkbox"/> Other reason:	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Is psychosocial treatment in place without adequate clinical response, and psychosocial treatment with parental involvement will continue for the duration of therapy?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Has informed consent for this medication been obtained from the parent or guardian?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Has a family assessment been performed (including parental psychopathology and treatment needs), and have family functioning and parent-child relationship been evaluated?</b>	
<b>NON-PREFERRED MEDICATIONS</b>		
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Has the patient demonstrated failure or intolerance to TWO preferred formulary alternatives for the given diagnosis? (If yes, complete "Previous Medication Trials/Contraindications" section on first page)</b> <i>If no, list reason:</i>	
<b>VRAYLAR</b>		
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Has the patient been receiving treatment with the requested non-preferred behavioral health medication and is new to the plan (enrollment effective date within the past 90 days)?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Is the patient currently receiving treatment with the requested non-preferred behavioral health medication in the hospital and must continue upon discharge?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Does the patient have a diagnosis of schizophrenia or schizoaffective disorder?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>If yes to the above question, does the patient have a history of failure, contraindication, or intolerance to THREE preferred alternatives, one of which must be aripiprazole?</b> <i>(If yes, complete "Previous Medication Trials/Contraindications" section on first page)</i>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Does the patient have a diagnosis of depressive episodes associated with Bipolar I Disorder (bipolar depression)?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>If yes to the above question, does the patient have a history of failure, contraindication, or intolerance to both quetiapine AND fluoxetine used in combination with olanzapine?</b> <i>(If yes, complete "Previous Medication Trials/Contraindications" section on first page)</i>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>Does the patient have a diagnosis of mania or mixed episodes associated with Bipolar Disorder?</b>	
<input type="checkbox"/> Yes <input type="checkbox"/> No	<b>If yes to the above question, does the patient have a history of failure, contraindication, or intolerance to THREE preferred alternatives, one of which must be aripiprazole?</b> <i>(If yes, complete "Previous Medication Trials/Contraindications" section on first page)</i>	

## Antipsychotics – Virginia Prior Authorization Request Form

Patient First name:	Patient Last name:	Patient DOB:
<b>ABILIFY MYCITE</b>		
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have tolerability to oral aripiprazole with suboptimal effects (as assessed by prescriber) that are due to adherence problems?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Has there been a documented intervention by prescriber for nonadherence [e.g. utilization of a pill box, utilization of a smart phone reminder (ex: alarm, application, or text reminder), involving family members or friends to assist, coordinating timing of dose to coincide with dosing of another daily medication]?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have a smart phone compatible with the device?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Has the patient given consent to a healthcare provider and caregiver (if applicable) to monitor the portal?	
<b>CONTINUATION OF THERAPY - ABILIFY MYCITE</b>		
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the prescriber attest that the patient has benefited from therapy?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the prescriber attest that there is a continued need for device (e.g., continued suboptimal effects and/or compliance)?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the healthcare provider and caregiver (if applicable) agree to continue to monitor device?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Has the patient had worsening of target symptoms?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Has the patient had any treatment-limited adverse effects (e.g., hypersensitivity, suicidality, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, pathological gambling and other compulsive behaviors, orthostatic hypotension, falls, seizures, cognitive and motor impairment, dysphagia, disruption in body temperature regulation, and leukopenia, neutropenia, and agranulocytosis)?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there a reason why the patient cannot use long acting injectable atypical antipsychotic if there is continued nonadherence? <i>If yes, document reason:</i>	
<b>QUANTITY LIMIT - CAPLYTA</b>		
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there rationale for needing to exceed the quantity limit of one capsule (42mg) per day? <i>If yes, provide rationale:</i>	

**Provider Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Confidentiality Notice:** This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.